2022
A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G
Weinzimer S, Bailey RJ, Bergenstal RM, Nimri R, Beck RW, Schatz D, Ambler-Osborn L, Schweiger DS, von dem Berge T, Sibayan J, Johnson ML, Calhoun P, Phillip M, Bergenstal R, Phillip M, Criego A, Bergenstal R, Carlson A, Martens T, Beasley S, Johnson M, Whipple D, Hyatt J, Punel A, Grieme A, Thomas L, LaFrance A, Hasledalen C, Laffel L, Isganaitis E, Freiner E, Ambler-Osborn L, Desrochers H, Turcotte C, Naik N, Roethke L, Fisher M, Nimri R, Nevo M, Bello R, Hamou A, Hermon O, Horesh O, Shiovitch Mantzuri G, Drotz I, Yehiel N, Naveh R, Schatz D, Haller M, Albanese-O'Neill A, Sheehan E, Leey J, Smith M, Jacobsen L, Adams J, Hosford J, Whyte L, Battelino T, Dovč K, Bratina N, Šmigoc Schweiger D, Sever U, Gianini A, Murn Berkopec B, Mali B, Weinzimer S, Weyman K, Carria L, Zgorski M, Danne T, Biester T, von dem Berge T, Weiskorn J, Kordonouri O, Biester S, Aschemeier B, Remus K, Pisarek N, Sibayan J, Beck R, Mouse T, Davis J, Bailey R, Hellmann A, Reese N, Calhoun P, Strayer H, Cohen N, Henderson R, Kollman C, Kennedy J, Woodall W, Mahr I, Hood K, Arreaza-Rubin G, Eggerman T, Green N, Janicek R, Gabrielson D, Belle S, Castle J, Green J, Legault L, Willi S, Wysham C, Eggerman T. A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G. Diabetes Technology & Therapeutics 2022, 24: 573-582. PMID: 35363054, PMCID: PMC9353997, DOI: 10.1089/dia.2021.0568.Peer-Reviewed Original ResearchConceptsHybrid closed-loop systemGlucose levelsGlycemic controlGlycemic excursionsAdvanced hybrid closed-loop systemG armPostprandial glycemic excursionsPostprandial glycemic controlType 1 diabetesPostprandial glucose controlPrandial insulin deliveryTreatment armsCrossover trialGlucose controlMedtronic MiniMedSecondary analysisMeal sizeOvernight improvementInsulin deliveryHyperglycemiaOutcomesArmLevel 2HypoglycemiaPremeal
2021
Predictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System
Schoelwer MJ, Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cobry EC, Messer LH, Cengiz E, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, Buckingham BA, Lal RA, Oliveri MC, Kollman CC, Dokken BB, Cherñavvsky DR, Beck RW, DeBoer MD, Gonder-Frederick L, Robic J, Voelmle M, Conschafter K, Morris K, Barnett C, Carr K, Hellmann J, Kime M, Todd Alonso G, Slover R, Berget C, Towers L, Lange S, Buckingham B, Maahs D, Lal R, Ekhlaspour L, Norlander L, Hood K, Town M, Weir C, Smith K, Hsu L, Shinksy D, Viana J, Cengiz E, Weinzimer S, Weyman K, Carria L, Zgorski M, Ruedy K, Beck R, Borgman S, Rusnak J, Kanapka L, Kollman C, Murphy C, Arreza-Rubin G, Green N, Kovatchev B, Brown S, Anderson S, Breton M, Laffel L, Pinsker J, Levy C, Kudva Y, Wadwa R, Buckingham B, Doyle III F, Renard E, Cobelli C, Reznik Y, Arreza-Rubin G, Lum J, Beck R, Ruedy K, Janicek R, Gabrielson D. Predictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System. Diabetes Technology & Therapeutics 2021, 23: 475-481. PMID: 33689454, PMCID: PMC8252894, DOI: 10.1089/dia.2020.0646.Peer-Reviewed Original ResearchConceptsGlycemic controlLower TIROptimal glycemic controlType 1 diabetesPredictors of timeGreater improvementClinical characteristicsClinical predictorsFourth quartileMore insulinBody weightGlucose monitor dataExtension phaseMultivariate modelBolusStrongest predictorContinuous glucose monitor dataQuartileInsulinPredictorsChildrenParticipantsT1D.T1DDiabetesExtended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes.
Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer MJ, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, DeBoer MD, Buckingham BA, Oliveri M, Kollman C, Dokken BB, Cherñavvsky D, Beck RW. Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes. Diabetes Care 2021, 44: 473-478. PMID: 33355258, PMCID: PMC7818334, DOI: 10.2337/dc20-1729.Peer-Reviewed Original ResearchConceptsType 1 diabetesChildren 6Sensor-augmented pump therapyWeeks of useDiabetic ketoacidosisDays of useGlycemic controlSAP groupSevere hypoglycemiaPump therapyClinical trialsPercentage of timeCLC groupMean TIRDiabetesFurther evaluationCohortRCTsDlWeeksChildrenDaysExtended useParticipantsKetoacidosis
2020
Brain Function Differences in Children With Type 1 Diabetes: A Functional MRI Study of Working Memory
Foland-Ross LC, Tong G, Mauras N, Cato A, Aye T, Tansey M, White NH, Weinzimer SA, Englert K, Shen H, Mazaika PK, Reiss AL, Tsalikian E, Tansey M, Coffey J, Cabbage J, Salamat S, Bisbee R, Mauras N, Fox L, Cato A, Englert K, Sikes K, Ewen T, Bird K, Buckingham B, Wilson D, Aye T, Kingman R, Weinzimer S, Tamborlane W, Ambrosino J, Steffen A, Weyman K, Zgorski M, White N, Arbelaez A, Levandoski L, Starnes A, Hershey T, Reiss A, Foland-Ross L, Marzelli M, Mazaika P, Tong G, Sperling M, Becker D, Cleary P, Greenbaum C, Moran A. Brain Function Differences in Children With Type 1 Diabetes: A Functional MRI Study of Working Memory. Diabetes 2020, 69: 1770-1778. PMID: 32471809, PMCID: PMC7372069, DOI: 10.2337/db20-0123.Peer-Reviewed Original ResearchConceptsType 1 diabetesImproved glycemic controlBrain function differencesFunctional MRI studyGreater modulationDiabetes groupGlycemic controlFrontoparietal cortexMRI studiesControl groupDiabetesType 1Functional MRICompensatory mechanismsEarly onsetBrain activationVisuospatial Working Memory TaskChildrenN-back taskMemory functionEarly ageMemory abilityWorking Memory TaskFuture studiesActivationPrecision Dosing of Rapid-Acting Insulin Matters
Aanstoot HJ, Rodriguez H, Weinzimer S, Vint N, Koeneman L. Precision Dosing of Rapid-Acting Insulin Matters. Diabetes Technology & Therapeutics 2020, 22: 346-351. PMID: 32125891, DOI: 10.1089/dia.2019.0374.Peer-Reviewed Original ResearchConceptsGood glycemic controlGlycemic controlHalf-unit insulin pensInsulin pensDiabetes managementInsulin deliveryStringent glycemic controlInadequate glycemic controlType 2 diabetesType 1 diabetesPrecision of dosingDelivery devicesInsulin delivery devicesInsulin therapyGeriatric patientsHypoglycemic eventsPatient preferencesFlexible dosingPhysical activityDosingLiterature searchPrecision dosingDiabetesInsulinCorrective doses
2019
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
Danne T, Pettus J, Giaccari A, Cariou B, Rodbard H, Weinzimer S, Bonnemaire M, Sawhney S, Stewart J, Wang S, de Cassia Castro R, Garg S. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2019, 21: 471-477. PMID: 31335194, PMCID: PMC6708262, DOI: 10.1089/dia.2019.0157.Peer-Reviewed Original ResearchConceptsSotagliflozin 200Insulin therapyHypoglycemia eventsRate of hypoglycemiaType 1 diabetesLevel 2 hypoglycemiaLower ratesImportant hypoglycemiaHypoglycemia ratesWeek 52Adult patientsGlycemic controlHypoglycemic eventsHypoglycemic rateClinical trialsInsulin treatmentPlaceboSotagliflozinHypoglycemiaType 1Phase 3PatientsTherapyWeeksAdults1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D
DANNE T, PETTUS J, GIACCARI A, CARIOU B, RODBARD H, WEINZIMER S, BONNEMAIRE M, SAWHNEY S, WANG S, CASTRO R, GARG S. 1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D. Diabetes 2019, 68 DOI: 10.2337/db19-1220-p.Peer-Reviewed Original ResearchOptimized insulin therapyInsulin therapySpouse/partnerSanofi USDiabetes careDohme Corp.Novo Nordisk A/SSanofi-AventisEli LillyMerck SharpAdvisory PanelPhase 3 studyLexicon PharmaceuticalsOptimal glycemic controlRisk of hypoglycemiaLevel 2 hypoglycemiaLower ratesAmgen Inc.Boehringer Ingelheim PharmaceuticalsDual SGLT1Important hypoglycemiaMannKind CorporationPatient yearsWeek 52Glycemic control
2018
Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial
Forlenza GP, Li Z, Buckingham BA, Pinsker JE, Cengiz E, Wadwa RP, Ekhlaspour L, Church MM, Weinzimer SA, Jost E, Marcal T, Andre C, Carria L, Swanson V, Lum JW, Kollman C, Woodall W, Beck RW. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. Diabetes Care 2018, 41: dc180771. PMID: 30089663, DOI: 10.2337/dc18-0771.Peer-Reviewed Original ResearchConceptsType 1 diabetesSAP armPredictive low glucose suspendSensor-augmented pump therapyNew insulin delivery systemsRandomized Crossover StudySevere hypoglycemic eventsGlucose concentrationMin/dayMean glucose concentrationLow glucose suspendBasal-IQRebound hyperglycemiaSlim X2Glycemic controlPrimary outcomeCrossover studyMedian timeCrossover trialHypoglycemic eventsPump therapyInsulin delivery systemsPercentage of timeHypoglycemiaDiabetesSotagliflozin in Combination with Optimized Insulin Therapy Reduced HbA1c Levels with a Decreased Daily Insulin Requirement after 52 Weeks in Adults with T1D
PETTUS J, WEINZIMER S, MCCRIMMON R, AMPUDIA BLASCO F, STEWART J, STRUMPH P, OLIVEIRA J, LAPUERTA P, CASTRO R. Sotagliflozin in Combination with Optimized Insulin Therapy Reduced HbA1c Levels with a Decreased Daily Insulin Requirement after 52 Weeks in Adults with T1D. Diabetes 2018, 67 DOI: 10.2337/db18-5-lb.Peer-Reviewed Original ResearchInsulin dose changesDaily insulin doseTotal daily insulin doseOptimized insulin therapyInsulin doseInsulin therapySevere hypoBolus insulinGlycemic controlLexicon PharmaceuticalsMycotic infectionsDose changesTreatment-emergent adverse eventsInsulin reductionLS meanDaily insulin requirementGenital mycotic infectionsSanofi-AventisAdequate glycemic controlGood glycemic controlBody mass indexRisk of hypoglycemiaRenal glucose reabsorptionNumber of patientsType of insulin
2017
Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System
Iturralde E, Tanenbaum ML, Hanes SJ, Suttiratana SC, Ambrosino JM, Ly TT, Maahs DM, Naranjo D, Walders-Abramson N, Weinzimer SA, Buckingham BA, Hood KK. Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System. The Science Of Diabetes Self-Management And Care 2017, 43: 223-232. PMID: 28340542, PMCID: PMC7162535, DOI: 10.1177/0145721717697244.Peer-Reviewed Original ResearchConceptsType 1 diabetesHybrid closed-loop systemFirst hybrid closed-loop systemLong-term complicationsGlycemic controlClinical trialsUS FoodDrug AdministrationMethods ThirtyDiabetesLife benefitsInsulin deliveryMental burdenT1DArtificial pancreasConclusion UsersAttitudes of individualsFocus groupsPerceived benefitsIndividualsComplicationsPancreasCliniciansAdministrationTrials
2016
Future Drug Treatments for Type 1 Diabetes
Sherr J, Cengiz E, Van Name M, Weinzimer S, Tamborlane W. Future Drug Treatments for Type 1 Diabetes. 2016, 985-999. DOI: 10.1002/9781118924853.ch66.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsInsulin analoguesDiabetes mellitusContinuous subcutaneous insulin infusion pumpType 2 diabetes mellitusType 1 diabetes mellitusInsulin deliveryBasal insulin analoguesNew treatment optionsFuture drug treatmentsAvailable insulin analoguesMore rapid absorptionClosed-loop deliveryDaily diabetes careAvailable insulin preparationsInsulin infusion pumpIntranasal glucagonInsulin therapyGlycemic controlAdjunctive agentsAvailable therapiesInjected medicationsDiabetes careTreatment optionsContinuous glucose monitorDrug treatmentAltered Integration of Structural Covariance Networks in Young Children With Type 1 Diabetes
Hosseini SM, Mazaika P, Mauras N, Buckingham B, Weinzimer SA, Tsalikian E, White NH, Reiss AL, Network F. Altered Integration of Structural Covariance Networks in Young Children With Type 1 Diabetes. Human Brain Mapping 2016, 37: 4034-4046. PMID: 27339089, PMCID: PMC5053865, DOI: 10.1002/hbm.23293.Peer-Reviewed Original ResearchConceptsEarly-onset T1DStructural covariance networksYoung childrenNeurocognitive deficitsType 1 diabetes mellitusCovariance networksBrain networksFrequent chronic diseasesHum Brain MappRegional gray matterGlycemic controlDiabetes mellitusGlucose dysregulationNeural insultsHealthy controlsLarge-scale brain networksChronic diseasesBulk of evidenceNeuroanatomical changesT1DWhite matterGray matterBrain developmentGraph theoretical analysisT1D.
2013
The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes DiagnosisDiabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups*
Buckingham B, Beck R, Ruedy K, Cheng P, Kollman C, Weinzimer S, DiMeglio L, Bremer A, Slover R, Cantwell M. The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes DiagnosisDiabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups*. Diabetes Technology & Therapeutics 2013, 15: 401-408. PMID: 23570538, PMCID: PMC3643224, DOI: 10.1089/dia.2013.0002.Peer-Reviewed Original ResearchConceptsType 1 diabetesMean glucose concentrationHybrid closed-loop controlMedian percentageHybrid closed-loop therapyType 1Sensor-augmented pump therapyPositive pancreatic autoantibodiesTrialNet Study GroupDays of diagnosisNormal glycemic controlΒ-cell functionGlucose concentrationClosed-loop therapyPancreatic autoantibodiesGlycemic controlSAP therapyPump therapyStudy groupGlucose levelsGlucose toxicityDay 2Day 3Glucose valuesTherapy
2008
Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes
Tamborlane W, Beck R, Bode B, Buckingham B, Chase H, Clemons R, Fiallo-Scharer R, Fox L, Gilliam L, Hirsch I, Huang E, Kollman C, Kowalski A, Laffel L, Lawrence J, Lee J, Mauras N, O'Grady M, Ruedy K, Tansey M, Tsalikian E, Weinzimer S, Wilson D, Wolpert H, Wysocki T, Xing D. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. New England Journal Of Medicine 2008, 359: 1464-1476. PMID: 18779236, DOI: 10.1056/nejmoa0805017.Peer-Reviewed Original ResearchConceptsYears of ageContinuous glucose monitoringContinuous monitoring groupPatients 25 yearsGlycated hemoglobin levelsType 1 diabetesHemoglobin levelsGlucose monitoringStudy groupControl groupType 1 diabetes mellitusMulticenter clinical trialBetween-group differencesHemoglobin outcomesYounger patientsDiabetes mellitusGlycemic controlIntensive therapyPrimary outcomeSevere hypoglycemiaClinical trialsIntensive treatmentAge groupsBlood glucose metersType 1
2007
Continuous Glucose Monitoring in Children with Type 1 Diabetes
Buckingham B, Beck R, Tamborlane W, Xing D, Kollman C, Fiallo-Scharer R, Mauras N, Ruedy K, Tansey M, Weinzimer S, Wysocki T. Continuous Glucose Monitoring in Children with Type 1 Diabetes. The Journal Of Pediatrics 2007, 151: 388-393.e2. PMID: 17889075, PMCID: PMC2045068, DOI: 10.1016/j.jpeds.2007.03.047.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringContinuous glucose monitorReal-time continuous glucose monitoringGlucose monitoringMean hemoglobin A1cSevere skin reactionsType 1 diabetesGlucose monitorContinuous glucose monitoring systemInsulin pump usersDaily useGlycemic controlHemoglobin A1cDaily treatmentGlucose monitoring systemSkin reactionsWeek 9Glucose valuesBaseline levelsType 1WeeksPump usersT1DHigh satisfactionChildren